Phase 2 N=14 Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Cystic Fibrosis
Primary: 6 Minute Walk Distance — 25.2; 0.75 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,055 Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.113; 0.095 Liter
N/A N=103 Mood and Influenza Vaccine Response: A Feasibility Trial
Vaccination; Infection
Primary: Mood Outcome Scores [Multiple] — 87.4; 79.8; 83.7; 79.8 score on a scale — p=.005
N/A N=175 Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation
Primary: Incidence of Esophageal Injury as Assessed by Endoscopy — 1; 12; 4; 0 participants
Phase 3 N=31 Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
Acute Coronary Syndrome
Primary: Change in the Total Atheroma Volume of the Target Coronary Artery From Baseline to 12 Weeks Post-PCI as Assessed Via Intravascular Ultrasound With Virtual Histology…
N/A N=298 Three Different Cardiopulmonary Resuscitation (CPR) Training Methods
Cardiopulmonary Resuscitation
Primary: CPR Depth — 43.7; 42.2; 35.3 millimeters
Phase 2 N=49 Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) — 33 Participants
N/A N=30 Muscle Fatigue and Scapular Sensorimotor System
Muscle; Fatigue
Primary: Change From Baseline in Scapular Proprioception — -0.48; -0.19; -0.37; -0.32 centimeters — p=0.227
Phase 1 N=12 Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
HIV-1 Infection
Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) at 168 Hours Post-Dose — -1.06; -0.95 log10 (copies/mL)
Phase 2 N=17 Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Basal Cell Nevus Syndrome
Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…
Phase 1 N=44 Glucophage Immediate Release (GIR) China Bioequivalence Study
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient) — 6260; 6280; 4950; 5020…
N/A N=61 Eating Behaviour in Crohn's Disease
Crohn's Disease
Primary: Dietary Recalls (Calorific Intake) — 1900.9; 2054.3 kcal
N/A N=1,030 The Midlands and North of England Stillbirth Study
Stillbirth
Primary: Maternal Sleep Practices During Pregnancy — 140; 383; 73; 220 Participants
N/A N=40 Intraoperative Case Series Study: Trial Rasp Position Versus SL-PLUS™ MIA Ti/HA Femoral Hip Stem Position
Osteoarthritis
Primary: Mean Difference D Between the Position of the Last Trial Rasp and the Final Implant Position of the SL-PLUS™ MIA Ti/HA Femoral Hip Stem as Measured by an Intraoperative…
N/A N=407 MiQuit Trial: Tailored Text Messages for Pregnant Women
Pregnancy · Smoking
Primary: Continuous Abstinence From Smoking Reported From 4 Weeks Post-randomisation Until Late Pregnancy, Biochemically Validated at Late Pregnancy. — 11; 4 Participants